Application of CD8 alpha positive macrophages in treatment of optic nerve injury

By applying CD8α-positive macrophages, the problem of limited regenerative capacity after optic nerve injury was solved, and the survival of retinal ganglion cells and significant recovery of visual function were achieved.

CN120617308APending Publication Date: 2025-09-12ZHEJIANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202511015448.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-23
Publication Date
2025-09-12

AI Technical Summary

Technical Problem

The optic nerve has limited regenerative capacity after injury, and existing treatments are difficult to effectively promote the survival of retinal ganglion cells and the recovery of visual function.

Method used

CD8α-positive macrophages are used to promote the survival and axon regeneration of retinal ganglion cells by regulating extracellular matrix remodeling, antioxidant and anti-apoptotic mechanisms.

Benefits of technology

Significantly improves the survival rate of retinal ganglion cells and improves visual function recovery, providing better visual effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120617308A_ABST
    Figure CN120617308A_ABST
Patent Text Reader

Abstract

The invention discloses an application of CD8 alpha positive macrophages in treatment of optic nerve injury. In the application, optic nerve injury treatment is specifically shown as follows: the survival of retinal ganglion cells after minor optic nerve injury is promoted; improving visual function recovery after optic nerve injury of the mouse, wherein the visual function recovery comprises retina ganglion cell function, retina function and vision recovery; the product is a medicine or a test reagent. Research shows that the survival rate of retina ganglion cells (RGCs) can be improved through CD8 alpha positive macrophage treatment, meanwhile, visual behavioral detection verifies that the CD8 alpha positive macrophage has a certain effect on long-term vision improvement of mice, and compared with an existing treatment method, the CD8 alpha positive macrophage is better in effect and has important clinical value, and the CD8 alpha positive macrophage has a good application prospect. And a new thought is provided for optic nerve injury treatment, so that the method has a good practical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine and molecular biology, and particularly relates to the application of bone marrow-derived CD8α-positive macrophages in the treatment of optic nerve damage. Background Art

[0002] Optic nerve injury (ONI) is a major cause of vision loss and blindness, and is commonly seen in diseases such as ocular trauma and optic neuritis. The optic nerve is part of the central nervous system (CNS), and its regenerative capacity after injury is extremely limited. This is mainly due to the activation of glial cells after injury, which forms glial scars and releases multiple axon growth inhibitors, such as chondroitin sulfate proteoglycans (CSPGs) and semaphorin 3A (Sema3A). In addition, post-injury inflammatory responses and oxidative stress can also exacerbate RGC apoptosis. Therefore, how to promote the survival of RGCs and axon regeneration is a key issue in the treatment of optic nerve injury.

[0003] CD8α-positive macrophages are a newly identified type of macrophage that possess some T cell functions as well as macrophage characteristics. They exhibit both pro-inflammatory and anti-inflammatory properties. They secrete a variety of matrix metalloproteinases and inflammatory cytokine balancers to regulate the inflammatory response. Therefore, utilizing CD8α-positive macrophages secreted by RGCs as a treatment for optic nerve injury has the potential to not only promote nerve regeneration but also ameliorate the pathological process following optic nerve injury through their antioxidant and anti-apoptotic effects. Summary of the Invention

[0004] In response to the shortcomings of the prior art, the present invention provides the use of CD8α-positive macrophages in the treatment of optic nerve injury. The present invention establishes an optic nerve crush (ONC) model to study the effects of CD8α-positive macrophages on RGC survival and visual function recovery. The results show that CD8α-positive macrophage treatment can significantly increase RGC survival and improve visual function recovery after optic nerve injury. Based on the above research results, the present invention is completed.

[0005] The technical solution adopted in the present invention is:

[0006] 1. Application of CD8α-positive macrophages in screening or preparing products for treating optic nerve damage.

[0007] The optic nerve injury treatment is specifically manifested as follows:

[0008] (a) Promotes the survival of retinal ganglion cells after small optic nerve injury;

[0009] (b) Improved visual function recovery after optic nerve injury in mice.

[0010] The visual function recovery includes retinal ganglion cell function, retinal function and vision recovery.

[0011] The product is a drug or a test reagent.

[0012] 2. A product for treating optic nerve damage.

[0013] The product comprises CD8α positive macrophages.

[0014] Specifically, the product is a medicine or a test reagent.

[0015] Furthermore, the drug also includes a pharmaceutically acceptable carrier.

[0016] Preferably, the drug is a CD8α-positive macrophage solution with a specific cell density.

[0017] Preferably, the concentration of the CD8α-positive macrophage solution is 150,000 / 1 μL.

[0018] Preferably, the CD8α-positive macrophages are derived from bone marrow.

[0019] The beneficial effects of the present invention are as follows:

[0020] 1. The present invention uses CD8α-positive macrophages to treat optic nerve damage, thereby reducing RGC apoptosis and promoting recovery from optic nerve damage. Results showed that after treatment with CD8α-positive macrophages, the survival rate of RGCs after optic nerve damage was significantly increased. At the same time, visual behavioral experiments demonstrated that CD8α-positive macrophages have a significant effect on the recovery of visual function after optic nerve damage. Moreover, CD8α-positive macrophages are more effective than existing treatment methods, have important clinical value, and provide new ideas for the treatment of optic nerve damage, thus having good practical application value.

[0021] 2. The present invention suggests that CD8α-positive macrophages are expected to become effective therapeutic cell drugs for optic nerve damage and other central nervous system injuries, providing new ideas and methods for the treatment of optic nerve damage, which has important clinical value and good practical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 Identification of CD8α-positive macrophages in optic nerve injury; A is a schematic diagram showing the experimental setup of scar tissue acquisition and single-cell sequencing; B is the expression of CD8α in scars after the addition of inducers. + Cd68 + Cd3e -Cluster diagram of macrophage population, showing high expression of macrophage markers such as Cd68, Adgre1, Itgam and Csf1r; n = 3 samples, each from 20 mice; C is a bubble diagram showing the Cd8α + Cd68 + Cd3e - Macrophages are enriched in M1 markers but less in M2 markers; D to G are representative flow cytometry images (F), optic nerve section images (D), and bar graphs (E and G), showing CD8α in scars of the control and depletion groups under induction conditions or in the corresponding areas of the sham group. + Percentage of macrophages (G, 8 mice per group) and density (E, 11 sections from 6 mice per group); scale bar, 50 μm; dashed curve in panel D represents CD8α + Cell aggregation area; all data are expressed as mean ± standard error; * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001.

[0023] Figure 2 Adoptive transfer of macrophages maintained the protection of retinal ganglion cells (RGCs) and restored visual function; A is a schematic diagram showing the experimental setup of adoptive transfer of macrophages; B is the transferred CD8α labeled with Cell Trace Far Red at the injury site + Macrophages; C and D are representative images (C) and corresponding bar graphs (D) of the retina, showing the effects of saline, CD8α - Macrophages and CD8α + Density of RGCs in whole-thickness mounts of macrophage-treated retinas (nine retinas from six mice per group); scale bar, 50 μm; E and F are traces (E) and bar graphs (F), respectively, of representative flash visual evoked potentials (FVEPs) in macrophage-treated retinas treated with saline, CD8α - Macrophages and CD8α + Amplitudes of FVEPs in macrophage-treated mice (n=6 mice per group); FVEPs: flash visual evoked potentials; G–I are bar graphs showing visual functions assessed in the visual cliff (G and H) and looming (I) tests, including the cumulative time spent in the shallow safe zone, preference for the shallow zone versus the deep zone (expressed as a percentage (left y-axis) or the number of shallow zone choosers (right y-axis)), and saline, CD8α - Macrophages and CD8α + Percentage (left y-axis) and number (right y-axis) of near responders in macrophage treatment; all data are expressed as mean ± SD; * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001.

[0024] Figure 3 Macrophage depletion abolishes retinal ganglion cell (RGCs) protection and visual function recovery; A is a schematic diagram showing the experimental setup of macrophage depletion; B is a flow cytometry graph and bar graph showing the expression of CD8α in blood after treatment with saline (Ctrl) or clodronate liposomes compared with sham-operated controls. + Percentage of macrophages; sham-operated, control liposome (control), and clodronate liposome (depletion) groups had 5, 5, and 4 mice, respectively; C to J are representative images of optic nerve sections (C and E), retinas (G), and RGC axons traced with AAV-eGFP virus (I), and corresponding bar graphs (D, F, H, and J) showing CD8α in scars treated with control liposomes (control) or clodronate liposomes (depletion) in the control (Ctrl) and inducer groups. + The density of macrophages (D, 6, 6, 6, and 7 sections from 5 mice in the groups of no inducer + control liposomes, inducer + control liposomes, no inducer + clodronate liposomes, and inducer + clodronate liposomes, respectively), the area of ​​scars in the optic nerve (F, 5, 6, 6, and 7 sections from 5 mice in the groups of no inducer + control liposomes, inducer + control liposomes, no inducer + clodronate liposomes, and inducer + clodronate liposomes, respectively), the density of RGCs in the retinal full-thickness flat mounts (H, liposomes, inducer + control liposomes, no inducer + clodronate liposomes, and inducer + clodronate liposomes groups, including 7, 6, 8, and 9 retinas from 5 mice, respectively) and RGC axons 500 μm away from the injury site (J, no inducer + control liposomes, inducer group + control liposomes, no inducer + clodronate liposomes, and inducer + clodronate liposomes groups, including 9, 8, 8, and 10 mice, respectively); scale bars: 50 μm in C, E, and G, 100 μm in I; the dashed curve in panel C represents CD8α + CD11b +Cell aggregation area; the dotted line in Figure I indicates 500 μm from the injury site; K and L are representative flash visual evoked potential (FVEP) traces (K) and bar graphs (L), respectively, showing the amplitudes of FVEPs in the no-inducer and inducer groups treated with control liposomes (control group) or clodronate liposomes (depletion group) (L, no-inducer + control liposomes, inducer + control liposomes, no-inducer + clodronate liposomes, and inducer + clodronate liposomes groups, including 9, 8, 9, and 8 mice, respectively); FVEPs: Flash visual evoked potential; M~O are bar graphs showing the visual functions assessed in the visual cliff (M and N) and looming (O) tests, including the cumulative time spent in the shallow safe zone (M, 9, 8, 9, and 8 mice in the no inducer + control liposomes, inducer + control liposomes, no inducer + clodronate liposomes, and inducer + clodronate liposomes groups, respectively), the preference for the shallow versus deep zone (expressed as percentage (left y-axis) or the number of shallow zone choosers (right y-axis)) (N, 10 mice in each group), and the expression of saline, CD8α - Macrophages and CD8α + Percentage (left y-axis) and number (right y-axis) of approach responders in macrophage treatment (O, 10 mice per group); all data are expressed as mean ± SD; * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001.

[0025] Figure 4 CD8α + Depletion of these cells results in the loss of protection of retinal ganglion cells (RGCs) and their axons and the loss of visual function recovery after optic nerve injury (ONC); A shows CD8α + Schematic diagram of the cell depletion experiment setup and subsequent experimental procedures; B is a flow cytometry graph and bar graph showing the expression of CD8α in blood after treatment with control IgG (control group) or anti-CD8α (depletion group) compared with sham-operated controls. + Percentage of macrophages; sham, cIgG, and anti-CD8α groups had 5, 4, and 5 mice, respectively; C to J are representative images of optic nerve sections (C and E) and retinas (G) and RGC axons traced with AAV-eGFP virus (I), and bar graphs (D, F, H, and J) showing CD8α in scars treated with control IgG (control group) or anti-CD8α (depletion group) in the no-inducer and inducer groups. +The density of macrophages (D), the area of ​​scars in optic nerve scars (F), the density of RGCs in full-thickness retinal mounts (H), and the number of RGC axons 500 μm away from the injury site (J); the number of sections from five mice in each group in D was 7, 8, 9, and 8, respectively; the number of mice in F was 5, 4, 5, and 4, corresponding to the no inducer + cIgG, inducer + cIgG, no inducer + anti-CD8α, and inducer + anti-CD8α groups, respectively; the number of retinas from five mice in each group in H was 6, 6, 7, and 7, respectively; the number of mice in J was 9, 10, 9, and 9, corresponding to the no inducer + cIgG, inducer + cIgG, no inducer + anti-CD8α, and inducer + anti-CD8α groups, respectively; scale bars: 50 μm in C, E, and G, 100 μm in I; the dotted curve in Figure C represents CD8α + CD11b + Cell aggregation area; the dotted line in Figure I indicates 500 μm from the injury site; K and L are representative flash visual evoked potential (FVEP) traces (K) and bar graphs (L), respectively, showing the amplitudes of FVEPs (L) in the no-inducer and inducer groups treated with control IgG (control group) or anti-CD8α (depletion group); 10 mice per group; FVEPs: flash visual evoked potentials; M–O are bar graphs showing visual function assessed in the visual cliff (M and N) and approach (O) tests, which are the cumulative time spent in the shallow safe zone (M), the preference for the shallow versus deep zone (expressed as percentage (left y-axis) or number of shallow zone choosers (right y-axis)) (N), and the percentage (left y-axis) and number (right y-axis) of approach responders (O), respectively; 10 mice per group; all data are expressed as mean ± standard error; * indicates P < 0.05, ** indicates P < 0.01, and *** indicates P < 0.001. DETAILED DESCRIPTION

[0026] It should be noted that the following detailed description is illustrative and is intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs.

[0027] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, it will be described in detail below with reference to specific embodiments.

[0028] The first invention of the present invention provides an application of CD8α-positive macrophages in screening or preparing products for treating optic nerve damage.

[0029] The inventors have discovered that CD8α-positive macrophages have significant potential in the treatment of optic nerve damage. CD8α-positive macrophages can promote RGC survival and axon regeneration by regulating extracellular matrix remodeling, anti-oxidation, and anti-apoptosis mechanisms, thereby improving visual function recovery after optic nerve damage.

[0030] In view of this, a typical embodiment of the present invention provides the use of CD8α-positive macrophages in preparing a product for treating optic nerve damage.

[0031] Specifically, the specific manifestations of optic nerve damage treatment are:

[0032] (a) Promotes the survival of retinal ganglion cells after optic nerve injury;

[0033] (b) Improving visual function recovery after optic nerve injury; wherein visual function recovery includes but is not limited to retinal ganglion cell function, retinal function and vision recovery.

[0034] Preferably, the CD8α-positive macrophages are derived from bone marrow. The present invention has found through research that CD8α-positive macrophages have a significant effect in the treatment of optic nerve damage.

[0035] The second invention of the present invention provides a product for treating optic nerve damage.

[0036] Specifically, the product contains the above-mentioned CD8α-positive macrophages.

[0037] CD8α-positive macrophages have the following functions:

[0038] (a) Promotes the survival of retinal ganglion cells after optic nerve injury;

[0039] (b) Improving visual function recovery after optic nerve injury; wherein visual function recovery includes but is not limited to retinal ganglion cell function, retinal function and vision recovery.

[0040] It should be noted that the product can be a drug or a test reagent. The test reagent is used for basic research and can be used to construct relevant cell or animal models.

[0041] Specifically, the drug is a cellular pharmaceutical composition comprising CD8α-positive macrophages.

[0042] When the product is a drug, the drug may also include a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers may be buffers, emulsifiers, suspending agents, stabilizers, preservatives, excipients, fillers, coagulants and conditioning agents, surfactants, dispersants or defoaming agents.

[0043] The drug can also be used in combination with other drugs for preventing and / or treating optic nerve damage and other central nervous system damage. Other preventive and / or therapeutic compounds can be administered simultaneously with the main active ingredient, or even in the same composition.

[0044] The drug can also be administered separately in the form of a separate composition or a dosage form different from the main active ingredient to other preventive and / or therapeutic compounds. Partial doses of the main ingredient can be administered simultaneously with other therapeutic compounds, while other doses can be administered separately. During the course of treatment, the dosage of the drug of the present invention can be adjusted according to the severity of the symptoms, the frequency of recurrence, and the physiological response of the treatment regimen.

[0045] The medicine of the present invention can be administered to the body in a known manner. For example, it can be delivered to the tissue of interest by systemic intravenous delivery or local injection. Alternatively, it can be administered intravenously, through the eye, skin, nose, mucous membrane or other delivery methods. Such administration can be carried out via a single dose or multiple doses. It will be appreciated by those skilled in the art that the actual dosage to be administered in the present invention can vary depending on various factors to a great extent, such as the target cell, biological type or tissue thereof, the general condition of the subject to be treated, the route of administration, the mode of administration, etc.

[0046] In some optional embodiments of the present invention, the product for treating optic nerve damage is a CD8α-positive macrophage solution with a specific cell density.

[0047] In the above optional embodiment, the concentration of the CD8α-positive macrophage solution is 150,000 / 1 μL.

[0048] The present invention is further explained by the following examples, but is not intended to limit the present invention. It should be understood that these examples are only intended to illustrate the present invention and are not intended to limit the scope of the present invention. All raw materials used in the examples are commercially available unless otherwise specified.

[0049] Example

[0050] 1. Materials and Methods

[0051] 1. Animal Model Preparation: Animal experiments were conducted in accordance with the International Guiding Principles for Animal Research provided by the Council for International Organizations of Medical Sciences (CIOMS). The procedures were approved by the Animal Ethics and Welfare Committee of the First Affiliated Hospital, Zhejiang University School of Medicine. Adult male C57BL / 6 mice were randomly divided into three groups, with 12 mice in each group.

[0052] ① Sham operation group: only the optic nerve was exposed without clamping;

[0053] ②Experimental group: bone marrow-derived CD8α-positive macrophages were injected into the injured optic nerve;

[0054] ③Control group: injected with normal saline.

[0055] ④ No inducer + depletion group: no inducer of CD8α-positive macrophages was added, but the cells were depleted by clodronate liposomes or anti-CD8 IgG antibodies;

[0056] ⑤ Inducer + depletion group: CD8α-positive macrophage inducer was added and cells were depleted by clodronate liposomes or anti-CD8 IgG antibodies;

[0057] ⑥ No inducer + control group: no inducer of CD8α-positive macrophages was added and control liposomes or control IgG was added without cell depletion;

[0058] ⑦ Inducer + control group: add inducer of CD8α-positive macrophages and add control liposomes or control IgG without depleting cells.

[0059] 1.1 Optic nerve damage:

[0060] Experimental mice were first induced into a deep state of anesthesia via intraperitoneal injection of 1% sodium pentobarbital (by weight). To ensure a painless surgical procedure and minimize blinking, a topical anesthetic (proparacaine hydrochloride eye drops) was applied to the cornea. Subsequently, the eye and surrounding area were thoroughly disinfected to reduce the risk of postoperative infection. During surgery, a small conjunctival incision was made on the side of the mouse's upper eyelid, and blunt dissection of the subconjunctival tissue, retrobulbar fat, and muscle was performed with blunt-tipped microforceps to fully expose the optic nerve. During ONC surgery, the optic nerve was clamped 1 mm posterior to the optic nerve head with constant force for 5 seconds to achieve stable, controlled injury. After the procedure, the conjunctival incision was carefully closed, and the eye and surrounding tissues were cleaned to remove any residue or secretions. Erythromycin ointment was applied to the operated eye to reduce postoperative infection. The mouse was placed on a heating pad and allowed to recover. Both eyes underwent the same surgical procedures. Mice in the sham-operated group underwent the same incision and optic nerve exposure procedures, but no optic nerve manipulation was performed to eliminate the effects of the surgical procedure itself. During the postoperative monitoring period, mice with ocular inflammation, corneal and lens opacities, and vitreous hemorrhage were discarded to ensure the reliability of the experimental results.

[0061] 1.2 Inclusion criteria for postoperative models: no turbidity in the mouse lens; no retinal hemorrhage or detachment; normal fundus blood supply; normal recovery of eye muscles, normal retraction without protrusion, and free rotation.

[0062] 2. Mouse Optic Nerve Injection

[0063] Mice were anesthetized with an injection of 1% sodium pentobarbital solution based on body weight. The ocular area was meticulously disinfected before surgery. A small incision was then made in the conjunctiva on the upper eyelid, carefully avoiding the sinus cavity. Fat and muscle tissue were bluntly dissected, and the optic nerve was exposed intraorbitally 1 mm from the eyeball. The ONC procedure was performed first, followed by an immediate injection of 150,000 CD8α-positive macrophages at a rate of 100 nL / min into the clamping site. Following the injection, the needle was slowly withdrawn to minimize trauma, and the ocular tissue was thoroughly cleaned to remove any residual drug solution. Erythromycin ointment was then applied to the eye. All surgical procedures were performed under a stereomicroscope to ensure precise drug delivery to the target site. All surgical instruments were autoclaved. After recovery from anesthesia, the mice were returned to their designated cages for continued care.

[0064] 3. Mouse Visual Behavior Experiment

[0065] 3.1 Flash visual evoked potential measurement

[0066] Measurements were performed using a Ganzfeld Q450 electrophysiological recorder, supported by a RETI-Port electrophysiological diagnostic system. Mice were generally anesthetized, their pupils dilated, and fixed to the experimental platform, ensuring full exposure to the instrument's light source. Recording electrodes were inserted into the occipital scalp to detect electrical activity in the visual cortex; a reference electrode was inserted subcutaneously in the cheek, and a ground electrode was fixed subcutaneously at the base of the tail. After confirming correct electrode placement, the mouse's eye was aligned with the stimulation system. The instrument then presented 64 white light flashes at a frequency of 1 Hz to elicit a FVEP. The amplitudes of the N1 to P1 (N1: first negative wave; P1: first positive wave) were analyzed using the Retiport electrophysiological diagnostic system. Dim lighting was maintained in the experimental room during testing, and the non-test eye was covered with opaque tape to prevent interference. After recording, the mice were closely monitored for any immediate adverse reactions or complications.

[0067] 3.2 Detection of visually induced instinctive defensive behavior

[0068] The mice were placed in an opaque observation chamber with a size of 45×45×45 cm. 3 , closed on all sides, with the top three-quarters of the area covered by a 50×30cm 2A display screen covered the entire chamber to present visual stimuli; the remaining quarter remained open to allow a wide-angle camera to record the mice's behavior. During the experiment, the only light source visible to the mice was a screen located on top of the test chamber, acting as a virtual sky. Before the experiment began, the mice were allowed to freely explore the chamber for 20 minutes. Subsequently, a gradually expanding black circle appeared on the screen as a looming visual stimulus (a "looming" paradigm), simulating a scenario in which mice are preyed upon by an aerial predator, such as a hawk. This stimulus was computer-generated, and its parameters (including the speed of the circle's movement, its size, and the distance of the screen from the bottom of the observation chamber) were calibrated to elicit characteristic defensive responses in mice with normal vision. The mice's displays of various defensive behaviors (such as "flee" and "freeze") were recorded and observed as indicators of their ability to detect danger and to characterize their visual function. After the experiment, the chamber was cleaned of feces and urine left by the mice and wiped with 75% alcohol to remove any remaining mouse odor before the next mouse was tested. Silence was maintained throughout the experiment, and all experiments were completed before 3:00 PM. This study was conducted using a double-blind analysis.

[0069] 3.3 Cliff Vision Test

[0070] Use a size of 45×45×45cm 3 The glass box is divided into two equal areas. One area is defined as the "safe zone" and has a grid pattern printed on the top; the other area is defined as the "unsafe zone" and has a grid pattern printed on the floor. The two sides have a depth difference, similar to a "cliff". In the initial stage of the test, a 5×5×45cm 3 A cube was placed above the dividing line between the two areas, and the mice were placed on top of the cube. The researchers observed whether the mice jumped off the cube within 10 minutes and recorded the area they jumped off. Mice that did not jump off within the specified time would be excluded. After 24 hours of rest, each mouse entered the second phase of the experiment. During the 5-minute observation period, the mice were allowed to freely explore the entire top of the box, and their movement trajectories were recorded using Any-maze (Stoelting, United States) software, and the time each mouse stayed in the "safe zone" was analyzed. In order to avoid the mice from habituating to the environment, each mouse was tested only once. After each experiment, the box and the central platform were carefully cleaned to ensure a sterile and consistent experimental environment for each test mouse. Keep quiet during the experiment, and all experiments were completed before 15:00 in the afternoon.

[0071] 4. Immunofluorescence Staining

[0072] 4.1 Retinal Flat-Mount Immunofluorescence Staining and Imaging of Mouse Retinal Flat-Mounts: Mice were deeply anesthetized and perfused intracardially. The eyeballs and optic nerves were then carefully removed, taking care not to disrupt the nerve. The retina was fixed in 4% PFA at room temperature for 2 hours. The cornea, iris, and lens were then dissected under a stereomicroscope. The retina was carefully separated from the choroid and sclera for subsequent staining.

[0073] 4.2 Retinal immunofluorescence staining: All sections were first incubated with blocking solution at room temperature for 2 hours to block nonspecific binding sites, and then incubated with primary antibodies at 4°C overnight. Subsequently, they were washed three times with PBS containing 0.1% Tween 20 (PBST), each for 10 minutes. After that, they were incubated with secondary antibodies labeled with Alexa Fluor 488, 546, 647, or 750 for 1 hour at room temperature in the dark. After incubation, they were washed again with PBST three times for 10 minutes each to remove excess secondary antibodies. Finally, the slides were air-dried and mounted with anti-fluorescence quenching mounting medium containing 4',6-diamidino-2-phenylindole (4',6-diamidino-2-phenylindole, DAPI).

[0074] 4.3 Preparation of mouse optic nerve slice samples

[0075] After perfusion, the mouse eyeballs were fixed in 4% PFA solution for 2 hours. Subsequently, the optic nerve was dissected and separated under a stereo microscope. The separated optic nerve was placed in a 30% sucrose solution for dehydration until the optic nerve settled to the bottom of the container. A drop of OCT embedding agent (Optimal Cutting Temperature Compound) was added to the slide, the optic nerve was carefully placed and straightened, and then lightly pressed with a coverslip to ensure that the optic nerve remained straight. It was quickly frozen to form a thin slice about 300 μm thick. After removal, it was trimmed into a rectangle containing the complete optic nerve along the direction of the optic nerve, and the rectangular slice was placed on a thicker, incompletely frozen OCT base. Cover with a slide and apply a weight of 200 g to it to ensure that the optic nerve remains straight and fused into the OCT base throughout the process. After it is frozen hard, it is removed and trimmed into a rectangular block again. Finally, the rectangular block containing the longitudinal optic nerve was affixed to a new OCT base. The blade was adjusted parallel to the optic nerve, ensuring that each section was cut along the longitudinal axis of the optic nerve into 10μm or 60μm thick frozen sections for subsequent staining. Sections were primarily collected from the middle third of the optic nerve cross-section, which is relatively wide, to reduce errors caused by irregular sections.

[0076] 4.4 Fluorescence Image Capture and Analysis

[0077] During confocal microscopy, the mercury lamp excitation intensity was first adjusted to minimum to ensure clear cell outlines. Imaging was performed using either the N-STORM / A1R system (equipped with 405 nm, 488 nm, 546 nm, and 647 nm filters) or the Leica STELLARIS8 system (equipped with 405 nm, 488 nm, 546 nm, 647 nm, and 750 nm filters). A 20× objective was used for imaging, and the laser excitation intensity was standardized across all channels to ensure consistent imaging conditions. The above steps were used to determine the level of CD8α-positive macrophages in the retinas of eyes with optic nerve injury and control eyes.

[0078] 5. Statistical Analysis

[0079] The sample size for each experiment ranged from 3 to 12 mice. Image analysis was performed using ImageJ software. Statistical analysis was performed using GraphPad Prism (version 8.0, GraphPad Software) or R (version 4.4.2, R language). No outliers were excluded during data analysis. Data normality was assessed using the Shapiro-Wilk test; two groups of data with a normal distribution were compared using the two-tailed unpaired Student's t-test; two groups with a non-normal distribution were compared using the Mann-Whitney test. Homogeneity of variance was assessed using the Brown-Forsythe test and the Bartlett test. One-way or two-way analysis of variance (ANOVA) with Dunnett's multiple comparison test was performed only when data were normally distributed and had homogeneous variance. For data sets with unequal variance and / or non-normal distribution, the Kruskal-Wallis test with post hoc Dunn's multiple comparison test was used. Data are presented as mean ± standard error (SEM), where * indicates P < 0.05, ** and ^^ indicate P < 0.01, and ***, ^^^, and ### indicate P < 0.001. To minimize subjective bias, image acquisition, cell counting, and data analysis were performed independently by different individuals. Furthermore, sample labeling was performed strictly according to the predefined sequence, and the statistical analysts remained blinded to the specific sample information until the data analysis was completed.

[0080] 2. Experimental Results

[0081] 1. Identification of CD8α-positive macrophages

[0082] By using single-cell sequencing ( Figure 1 Figures A and B show that after optic nerve injury, a group of Cd8α + Cd68 + Cd3e -Macrophages, and this group of cells tends to be M1 type, that is, pro-inflammatory type ( Figure 1 Figure C). The existence of this group of cells was also verified by immunofluorescence staining and flow cytometry of the optic nerve ( Figure 1 Figures D to G).

[0083] 2. Role of CD8α-positive macrophages

[0084] like Figure 2 As shown, CD8α-positive macrophages were injected into the optic nerve ( Figure 2 Figures A and B) can better preserve the cell body of RGC ( Figure 2 Figures C and D) and visual function ( Figure 2 Figures E to I).

[0085] Figure 2 Figures C and D showed through immunofluorescence staining that the number of RGCs retained after CD8α-positive macrophage injection was significantly increased compared with the control group.

[0086] Figure 2 Figures E and F show that the FVEP examination showed that the cortical evoked potential of mice was significantly enhanced after injection of CD8α-positive macrophages compared with the control group.

[0087] Figure 2 Figures G and H show that the depth perception of mice was significantly improved after injection of CD8α-positive macrophages compared with the control group through the visual cliff experiment.

[0088] Figure 2 Figure I shows that the Looming experiment shows that compared with the control group, the mice's ability to recognize shadows was significantly improved after injection of CD8α-positive macrophages.

[0089] 3. The impact of depleting macrophages in the blood

[0090] like Figure 3 As shown, macrophage depletion abolished retinal ganglion cell (RGCs) protection and visual function recovery.

[0091] Figure 3 Panels A and B demonstrate successful depletion of macrophages in blood by flow cytometry.

[0092] Figure 3 Figures C and D showed through immunofluorescence staining that the inducer can successfully induce CD8α-positive macrophages to accumulate in the injury scar, while the macrophages in the injury scar of the depletion group no longer accumulate significantly.

[0093] Figure 3Figures E and F showed through immunofluorescence staining that compared with the control group, the inducer-induced macrophages could significantly reduce the scar area surrounded by astrocytes, while there was no significant effect after depletion of macrophages in the blood.

[0094] Figure 3 Figures G and H showed through immunofluorescence staining that compared with the control group, the induction of macrophages by the inducer significantly increased the number of retained RGCs, while there was no significant effect after depletion of macrophages in the blood.

[0095] Figure 3 Figures I and J show that viral tracing was used to show that the induction of macrophages by the inducer significantly increased the number of retained axons compared with the control group, while depletion of macrophages in the blood had no significant effect.

[0096] Figure 3 The K and L graphs of FVEP examination showed that compared with the control group, the inducer-induced macrophages could significantly increase the cortical evoked potential of mice, while there was no significant effect after depletion of macrophages in the blood.

[0097] Figure 3 The M and N figures of the visual cliff experiment found that compared with the control group, the inducer-induced macrophages can significantly improve the depth vision of mice, while there is no significant effect after depleting the macrophages in the blood.

[0098] Figure 3 Figure O is a Looming experiment showing that compared with the control group, the inducer-induced macrophages can significantly increase the mice's ability to recognize shadows, while depleting the macrophages in the blood has no significant effect.

[0099] 4. Effects of depleting CD8α-positive cells in the blood

[0100] like Figure 4 As shown, CD8α + Depletion of these cells results in loss of protection of retinal ganglion cells (RGCs) and their axons and loss of visual function recovery after optic nerve injury (ONC).

[0101] Figure 4 Panels A and B demonstrate successful depletion of CD8α-positive cells in the blood by flow cytometry sorting.

[0102] Figure 4 Figures C and D showed that the inducer could successfully induce CD8α-positive macrophages to accumulate in the injured scar through immunofluorescence staining, while the macrophages in the injured scar of the depletion group no longer accumulated significantly.

[0103] Figure 4Figures E and F showed through immunofluorescence staining that compared with the control group, the inducer-induced CD8α-positive cells could significantly reduce the scar area surrounded by astrocytes, while there was no significant effect after depletion of CD8α-positive cells in the blood.

[0104] Figure 4 Figures G and H showed through immunofluorescence staining that compared with the control group, the induction of CD8α-positive cells by the inducer significantly increased the number of retained RGCs, while there was no significant effect after depletion of CD8α-positive cells in the blood.

[0105] Figure 4 Figures I and J show that viral tracing was used to show that compared with the control group, the induction of CD8α-positive cells by the inducer significantly increased the number of retained axons, while depletion of CD8α-positive cells in the blood had no significant effect.

[0106] Figure 4 The K and L graphs of FVEP examination showed that compared with the control group, the inducer-induced CD8α-positive cells could significantly increase the cortical evoked potential of mice, while there was no significant effect after depletion of CD8α-positive cells in the blood.

[0107] Figure 4 The M and N figures of the visual cliff experiment found that compared with the control group, the inducer-induced CD8α-positive cells could significantly improve the depth vision of mice, while there was no significant effect after depleting the CD8α-positive cells in the blood.

[0108] Figure 4 The O figure showed through the Looming experiment that compared with the control group, the inducer-induced CD8α-positive cells can significantly increase the mice's ability to recognize shadows, while there is no significant effect after depleting the CD8α-positive cells in the blood.

[0109] The results showed that CD8α-positive macrophages in the blood can significantly promote the recovery of visual function in mice.

[0110] In summary, this study established an optic nerve injury (ONC) model and investigated its effects on retinal and visual behavioral changes in mice after ONC by administering CD8α-positive macrophages. The results demonstrated that CD8α-positive macrophage therapy improved the survival rate of retinal ganglion cells (RGCs). Visual behavioral testing also confirmed its effect on long-term vision improvement in mice. Furthermore, CD8α-positive macrophage therapy demonstrated superior efficacy compared to existing treatments, demonstrating significant clinical value and providing new insights into the treatment of optic nerve injury. Therefore, it possesses promising practical applications.

[0111] The foregoing description is merely a preferred embodiment of the present invention and is not intended to limit the present invention. Those skilled in the art will readily appreciate that various modifications and variations of the present invention are possible. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present invention shall be included within the scope of protection of the present invention.

Claims

1. A method for screening or preparing a product for treating optic nerve damage using CD8α-positive macrophages.

2. The use according to claim 1, characterized in that: The optic nerve injury treatment is specifically manifested in: (a) promoting the survival of retinal ganglion cells after small optic nerve injury; and (b) improving the visual function recovery of mice after optic nerve injury.

3. The use according to claim 2, characterized in that: The visual function recovery includes retinal ganglion cell function, retinal function and vision recovery.

4. The use according to claim 1, characterized in that: The product is a drug or a test reagent.

5. A product for treating optic nerve damage, characterized in that: The product comprises CD8α positive macrophages.

6. The product according to claim 5, characterized in that: The product is a drug or a test reagent.

7. The product according to claim 6, characterized in that: The drug further includes a pharmaceutically acceptable carrier.

8. The product according to claim 6, characterized in that: The medicine is a CD8α positive macrophage solution with a specific cell density.

9. The product according to claim 8, characterized in that: The concentration of the CD8α-positive macrophage solution is 150,000 / 1 μL.

10. The product according to any one of claims 5 to 9, characterized in that: CD8α-positive macrophages originate from the bone marrow.